5 not yet recruiting, 3 unknown, 2 recruiting, 1 active not recruiting. 7 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 4, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Locally Advanced Colorectal Cancer: new trials by email Literature Review of Locally Advanced Colorectal Cancer trials Research Report on Locally Advanced Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) - Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer | Phase 1 | Not yet recruiting | Centre Georges Francois Leclerc | 77 | 2026-11-01 | 2026-05-14 |
| Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Serplulimab, CAPOX, Bevacizumab - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Xijing Hospital | 85 | 2026-09-01 | 2026-09-15 |
| Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine) - Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 35 | 2026-06-30 | 2026-07-09 |
| Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer Mitomycin (MM), FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Cytoreductive surgery - Locally Advanced Colorectal Cancer | Phase 3 | Recruiting | Maimónides Biomedical Research Institute of Córdoba | 1083 | 2026-05-26 | 2026-06-08 |
| Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer SHR-1701, SHR-8068, Short-course radiotherapy - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 134 | 2026-04-01 | 2026-03-31 |
| Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer ADG126, Pembrolizumab - Locally Advanced Colorectal Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 20 | 2025-04-14 | 2025-07-25 |
| Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy - Locally Advanced Colorectal Cancer, Postoperative Adjuvant Therapy | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 80 | 2024-10-01 | 2024-09-19 |
| Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine) - Locally Advanced Colorectal Cancer | Phase 4 | Unknown | yangjianjun | 20 | 2024-09-01 | 2024-11-12 |
| CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer Capecitabine, Oxaliplatin, Dihydroartemisinin - Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | Shanghai Changzheng Hospital | 15 | 2024-07-01 | 2026-09-03 |
| PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer PD-1 Antibody, Oxaliplatin, Capecitabine - DMMR Colorectal Cancer, MSI-H Colorectal Cancer | Phase 2 | Unknown | Sun Yat-sen University | 25 | 2020-07-31 | 2024-04-23 |
| Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) Standard adjuvant systemic chemotherapy, Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin - Locally Advanced Colorectal Cancer | Phase 3 | Unknown | Fudan University | 147 | 2016-11-01 | 2018-06-19 |
Colorectal Neoplasms (4) · Pancreatic Neoplasms (1)
Colonic Diseases (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Neoplasms (4) · Neoplasms by Site (4) · Rectal Diseases (4) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Pancreatic Diseases (1)
Capecitabine (6) · Oxaliplatin (6) · Bevacizumab (2) · Fluorouracil (2) · Leucovorin (2) · Cytoreduction Surgical Procedures (1) · Decitabine (1) · Folfox protocol (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Ipilimumab (1) · Medicine, Chinese Traditional (1) · Mitomycin (1) · Palliative Care (1) · SHR-1701 (1) · XELOX (1)
Fudan University (2) · Centre Georges Francois Leclerc (1) · Maimónides Biomedical Research Institute of Córdoba (1) · National University Hospital, Singapore (1) · Shanghai Changzheng Hospital (1) · Sir Run Run Shaw Hospital (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Xijing Hospital (1) · yangjianjun (1)
China (6) · France (1) · Singapore (1) · Spain (1)
Guoxiang Cai, M.D. Ph.D. (1) · Haiyang Zhou, MD (1) · Liu Hong (1) · Wei Peng Yong, MD (1)
PMID 10623705, PMID 11309435, PMID 24595805, PMID 26179333, PMID 26240218, PMID 29556198, PMID 29590544, PMID 29622799, PMID 31557064, PMID 32079180, PMID 33178737, PMID 33987095, PMID 34725214, PMID 35063964, PMID 35143424, PMID 35263150, PMID 36240854, PMID 36856579, PMID 37004094, PMID 38336371, PMID 38564700, PMID 39238638
2025 (2)